Mitral valve diseases are very common in both developed and developing countries and considerably affect mortality and morbidity. [1] [2] [3] [4] [5] The optimal timing for the surgical treatment of valve disease is before the permanent myocardial damage and serious symptoms occur. [6] Mitral valve diseases include both mitral valve stenosis and regurgitation. In addition, structural valve disease became surgically treatable after the introduction of the cardiopulmonary bypass system. Replacement of the damaged valve was the first choice in surgical treatment, since it is easier to perform and the results are more predictable. However, mitral valve repair (MVr) has become more popular, since mitral valve replacement (MVR) is associated with a high risk of thromboembolism, endocarditis, and left ventricular dysfunction. [7] [8] [9] Furthermore, it is necessary to use anticoagulants after MVR. In addition, MVr has a lower risk of thromboembolism and valvular infections, and requires less reoperation. [10] It is more popular thanks to these advantages. [10, 11] On the other hand, although repair is more popular today, MVR still has more advantages in certain conditions. Mitral valve replacement is in favor in patients with ischemic valvular disease, as MVr takes more time and, therefore, the duration of cardiopulmonary bypass machine use is longer. [12] Furthermore, MVr needs a great knowledge about the mitral valve morphology and structure, and an adequate experience. Nonetheless, previous studies have shown no significant difference between MVR and MVr in terms of long-time survival and mortality rates in patients with ischemic mitral valve disease. [13, 14] Although there are some new advanced biomaterials designed for valve production, they are still far from being the ideal materials. Neither mechanical nor biological valves are as ideal, as the patient's own valve. Although biological valves function much more like the natural valve of the human heart, they still tend to become deteriorated and need a replacement in a shorter time of period, compared to the mechanical valves. [15] Therefore, we can suggest that there is no prosthetic valve which provides an excellent hemodynamic properties without causing early and late mortality risks and not easy to supply and cannot be used by all surgeons. [16] Both of these two techniques have some superiority against each other. The primary goal is to heal the disease and to protect the functional capacity in the treatment of the patients with mitral valve disease. Therefore, one of the major outcomes of the treatment is to improve the quality of life (QoL) in these patients.
In the present study, we aimed to investigate the effects of MVR and MVr on the improvements in the QoL.
PATIENTS AND METHODS
A total of 40 patients (27 which is a questionnaire with 36 questions concerning the QoL and health care, was used to assess QoL of the patients at baseline and at six months of surgery. Face-to-face interview method was used to make sure that the patient fully understood the questions in the SF-36 scale. All patients were divided into two groups as group 1 (MVR, n=22) and group 2 (MVr, n=18). The patients who underwent only mitral and tricuspid valve interventions were included, and those who underwent double valve replacement or additional procedures (coronary artery bypass grafting or ascending aorta aneurysm repair) were excluded. Data including age and gender, diabetes mellitus, tobacco use, hypertension, cerebrovascular stroke, renal insufficiency, EuroSCORE, and myocardial infarction were recorded. Following parameters were investigated in the preoperative echocardiograms: stenosis (pure stenosis, predominant stenosis, predominant insufficiency, pure insufficiency) and diastolic diameter of the left ventricle, ejection fraction (EF), left atrium diameter, and mean pulmonary artery pressure. Cross-clamp and cardiopulmonary bypass times were also recorded. The mean body surface area was calculated.
The study was approved by the local Ethics Committee and conducted in accordance with the principles of the Declaration of Helsinki.
Surgical technique
A written informed consent was obtained from each patient. All operations were performed by three different surgical teams at a single-center, using the same surgical principles. Median sternotomy was used in both groups. Right atriotomy and transseptal incision were performed in tricuspid annuloplasty patients. The mitral valve was reached via only the left atriotomy in patients who were treated for only mitral valve dysfunction. The valve was excised and Tef lon-pledged sutures (2.0 polyester, Ethicon Inc., Somerville, NJ, USA) were used to implant the mitral valve. Different techniques were used to repair the mitral valve such as commissurotomy, quadrangular resection, and sliding annuloplasty, posterior annuloplasty, and cleft repair.
Statistical analysis
Statistical analysis was performed using the Number Cruncher Statistical System (NCSS, LLC, Kaysville, Utah, USA). Descriptive data were expressed in mean + standard deviation. The Student's t-test was used to compare normally distributed variables, while the Mann-Whitney U test was used to compare abnormally distributed variables between the two groups. The Wilcoxon sign test was used to analayze intra-group variables. The Fisher's exact and FisherFreeman-Halton tests were carried out to compare qualitative data. A p value of <0.05 was considered statistically significant.
RESULTS
A total of 22 patients underwent MVR, while 18 patients underwent MVr. None of the patients died after the operation until sixth month of the postoperative period. Baseline EF was 55.86% and 60.28%, while baseline EuroSCORE was 2.5 and 2.78 in group 1 and group 2, respectively ( Table 1) . Mitral valve disease had rheumatic and degenerative etiology in 29 and 11 patients, respectively. Thirty patients were classified as the New York Heart Association (NYHA) Class II, while the remaining 10 patients were classified as the NYHA III. There was no
When the preoperative findings were evaluated, EF and tobacco use were found to be significantly higher in group 2 (p<0.05). Although a higher Class III NHYA classification was found in group 2, it was not statistically significant (p>0.05). Severe heart failure was found to be higher in group 1, although it did not reach statistical significance (p>0.05). Baseline rhythm was atrial fibrillation in nine patients in group 1 and three patients in group 2 ( Table 2 ).
In addition, seven of eight domains of the SF-36 including physical function, role limitation due to physical function, social function, role limitation due to emotional problems, energy, mental health, and general health perception were significantly improved after the treatment in both groups (p<0.05). The increases in these domains were also similar in both groups (p>0.05) ( Table 3 ).
There was no significant increase in terms of pain scores in group 1 (p>0.05), although pain scores significantly increased in group 2 (p<0.01). The increase was not significantly different between two groups (p>0.05). There was a significant increase in terms of general health perception scores and energy in both groups (p<0.01), while the increase was similar in both groups (p>0.05). The social function scores increased in both group 1 (p<0.05) and group 2 (p<0.1), although the increase was statistically significant in group 2 only. However, there was no significant difference in the social function scores between the two groups.
DISCUSSION
Chronical mitral valve disease is related with significant mortality and morbidity. [17, 18] Thus, one of the primary goals of MVR or MVr is to reduce the mortality and morbidity rates. Although both methods have some superiority to each other, there are no strict rules about the order of the method that needs to be selected in a specific type of the disease. In this study, we investigated the effects of both treatment on the QoL of the patients using the SF-36 scale. Group It is not always possible to prevent mitral valve regurgitation after MVr. Soon or later, regurgitation is expected to recur. In the presence of a significant level of calcification or fibrosis, it is reasonable to perform a MVR operation to decrease the need for reoperation. In a recent meta-analysis, MVR and repair were compared in terms of multiple factors and it was found that MVr was related to an increased reoperation risk in patients with progressive rheumatic mitral valve disease. [19] It was also reported that there was no significant difference between MVR and MVr in terms of the survival rates in patients with ischemic mitral valve disease. [20] [21] [22] However, 30 days of mortality reduced in patients who underwent MVr. In another study, MVr was found to be related to a longer survival, and valve replacement was a risk factor in terms of long-term mortality. [23] Based on our findings, we can conclude that the method to be chosen for patients with mitral valve disease needs a multi-factorial assessment including age, etiology, comorbidities, additional cardiac pathologies, and severity of the mitral valve disease. Previous studies Group 
also showed that MVr was related with a lower incidence of in-hospital mortality, longer survival, increased left ventricle functions, and a lower risk of valve-related complications. [24] [25] [26] Accordingly, MVr is more popular, particularly in patients in whom the ventricular function should be preserved carefully. [27, 28] The primary goal of mitral valve operation is to heal the disease, while protecting the functional capacity. Of note, the main goal of all treatment modalities should be to improve the QoL of patients.
Furthermore, we found significantly improved pain scores in group 2 (p<0.01), while no statistically significant improvement was seen in group 1 (p>0.05). This finding is also consistent with the finding in a previous study.
[ 29] In the aforementioned study, however, Goldsmith and Patel [29] compared preoperative SF-36 results with third-month results. In another study, prognosis was reported to be poor in patients with an EF <50% and left ventricle dysfunction. [6] In addition, Goldsmith and Patel [29] found no significant improvement in the QoL of the patients with an EF value lower than 50%. Our study included only three patients with an EF value lower than 50%, and a significant improvement was seen in the QoL of these three patients.
The major limitations of the present study include being a single-center study, performing all operations by three different surgical teams, a small sample size, and not having mechanical and biological valve replacements in two different groups.
In conclusion, our study results show a significant improvement in the quality of life following both treatments. However, mitral valve repair seems to be superior to mitral valve replacement in terms of pain scores.
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